Trial Profile
A Randomized, Multicenter, Phase 2 Study to Compare the Efficacy of Panitumumab in Combination With mFOLFOX6 to the Efficacy of Bevacizumab in Combination With mFOLFOX6 in Patients With Previously Untreated, KRAS Wild-Type, Unresectable, Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms PEAK
- Sponsors Amgen
- 04 Jul 2020 Results of retrospective analysis of two studies PRIME and PEAK presented at the 22nd World Congress on Gastrointestinal Cancer
- 17 Jul 2018 Results published in the British Journal of Cancer
- 01 Feb 2018 Results of pooled data from PRIME (NCT00364013), PEAK (NCT00819780) and PLANET (NCT00885885) assessing impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment with panitumumab, were published in the Journal of Cancer Research and Clinical Oncology.